Godfred O Antwi1, Darson L Rhodes2. 1. Department of Public Health and Health Education, SUNY Brockport, 350 New Campus Drive, NY, 14420, Brockport, USA. gantwi@brockport.edu. 2. Department of Public Health and Health Education, SUNY Brockport, 350 New Campus Drive, NY, 14420, Brockport, USA.
Abstract
PURPOSE: Though prior studies have observed significant association between e-cigarette use and mental health outcomes including depression in the general population, the relationship between e-cigarette use and clinical depression in the cancer survivor subpopulation is unknown. The purpose of this study was to examine the cross-sectional association between e-cigarette use and self-reported clinical depression among cancer survivors. METHODS: Pooled data from the 2017 and 2018 Behavioral Risk Factor Surveillance Survey were used. Multivariable logistic regression was used to analyze the independent association between e-cigarette use and self-reported clinical depression in a sample of 7,498 cancer survivors. RESULTS: Among cancer survivors in this study, 22.1% reported a history of clinical diagnosis of depression. The overall prevalence rates for current and former e-cigarette use were 2.6% and 10.5%, respectively. Analysis showed 51.3% of current users, 40% of former users, and 19.1% of those who had never used e-cigarettes self-reported a history of clinical depression. In the multivariable analysis, the odds of self-reported clinical depression were significantly higher for survivors who were current users (OR = 2.85; 95% CI: 1.38-5.90) and former users (OR = 1.63; 95% CI: 1.05-2.55) compared to never e-cigarette users. CONCLUSION: Findings from this study suggest a statistically significant association between e-cigarette use and depression in cancer survivors. Future studies should focus on examining the longitudinal association between e-cigarette use and depression in cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Study findings reemphasized the need for interventions to support cancer survivors with evidence-based treatments for depression as well as the need for clinicians to screen for psychological distress and/or e-cigarette use and make appropriate recommendations.
PURPOSE: Though prior studies have observed significant association between e-cigarette use and mental health outcomes including depression in the general population, the relationship between e-cigarette use and clinical depression in the cancer survivor subpopulation is unknown. The purpose of this study was to examine the cross-sectional association between e-cigarette use and self-reported clinical depression among cancer survivors. METHODS: Pooled data from the 2017 and 2018 Behavioral Risk Factor Surveillance Survey were used. Multivariable logistic regression was used to analyze the independent association between e-cigarette use and self-reported clinical depression in a sample of 7,498 cancer survivors. RESULTS: Among cancer survivors in this study, 22.1% reported a history of clinical diagnosis of depression. The overall prevalence rates for current and former e-cigarette use were 2.6% and 10.5%, respectively. Analysis showed 51.3% of current users, 40% of former users, and 19.1% of those who had never used e-cigarettes self-reported a history of clinical depression. In the multivariable analysis, the odds of self-reported clinical depression were significantly higher for survivors who were current users (OR = 2.85; 95% CI: 1.38-5.90) and former users (OR = 1.63; 95% CI: 1.05-2.55) compared to never e-cigarette users. CONCLUSION: Findings from this study suggest a statistically significant association between e-cigarette use and depression in cancer survivors. Future studies should focus on examining the longitudinal association between e-cigarette use and depression in cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Study findings reemphasized the need for interventions to support cancer survivors with evidence-based treatments for depression as well as the need for clinicians to screen for psychological distress and/or e-cigarette use and make appropriate recommendations.
Authors: Godfred O Antwi; David K Lohrmann; Wasantha Jayawardene; Angela Chow; Cecilia S Obeng; Aaron M Sayegh Journal: J Cancer Surviv Date: 2019-04-06 Impact factor: 4.442
Authors: Eric Winer; Julie Gralow; Lisa Diller; Beth Karlan; Patrick Loehrer; Lori Pierce; George Demetri; Patricia Ganz; Barnett Kramer; Mark Kris; Maurie Markman; Robert Mayer; David Pfister; Derek Raghavan; Scott Ramsey; Gregory Reaman; Howard Sandler; Raymond Sawaya; Lynn Schuchter; John Sweetenham; Linda Vahdat; Richard L Schilsky Journal: J Clin Oncol Date: 2008-12-22 Impact factor: 44.544
Authors: Mohammadhassan Mirbolouk; Paniz Charkhchi; Sina Kianoush; S M Iftekhar Uddin; Olusola A Orimoloye; Rana Jaber; Aruni Bhatnagar; Emelia J Benjamin; Michael E Hall; Andrew P DeFilippis; Wasim Maziak; Khurram Nasir; Michael J Blaha Journal: Ann Intern Med Date: 2018-08-28 Impact factor: 25.391